ID   BRD3_HUMAN              Reviewed;         726 AA.
AC   Q15059; B1APD9; Q4G5Y3; Q5T1R7; Q8N5M3; Q92645;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 197.
DE   RecName: Full=Bromodomain-containing protein 3;
DE   AltName: Full=RING3-like protein;
GN   Name=BRD3; Synonyms=KIAA0043, RING3L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N.,
RA   Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II. The
RT   coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=16008511; DOI=10.1089/dna.2005.24.432;
RA   Ishii H., Mimori K., Mori M., Vecchione A.;
RT   "Differentially expressed genes in endothelial differentiation.";
RL   DNA Cell Biol. 24:432-437(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 363-726.
RX   PubMed=9373153; DOI=10.1016/s0378-1119(97)00415-0;
RA   Thorpe K.L., Gorman P., Thomas C., Sheer D., Trowsdale J., Beck S.;
RT   "Chromosomal localization, gene structure and transcription pattern of the
RT   ORFX gene, a homologue of the MHC-linked RING3 gene.";
RL   Gene 200:177-183(1997).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH ACETYLATED CHROMATIN.
RX   PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018;
RA   LeRoy G., Rickards B., Flint S.J.;
RT   "The double bromodomain proteins Brd2 and Brd3 couple histone acetylation
RT   to transcription.";
RL   Mol. Cell 30:51-60(2008).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH NUTM1.
RX   PubMed=17934517; DOI=10.1038/sj.onc.1210852;
RA   French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J.,
RA   Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R.,
RA   Fletcher J.A., Aster J.C.;
RT   "BRD-NUT oncoproteins: a family of closely related nuclear proteins that
RT   block epithelial differentiation and maintain the growth of carcinoma
RT   cells.";
RL   Oncogene 27:2237-2242(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-414, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [17]
RP   STRUCTURE BY NMR OF 25-415.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first and second bromodomain from human
RT   bromodomain containing protein 3.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.36 ANGSTROMS) OF 24-416, SUBUNIT, AND DOMAIN.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 307-416 IN COMPLEX WITH
RP   ACETYLATED HISTONE H3 PEPTIDE, FUNCTION, AND DOMAIN.
RX   PubMed=27105114; DOI=10.1016/j.molcel.2016.03.028;
RA   Li Y., Sabari B.R., Panchenko T., Wen H., Zhao D., Guan H., Wan L.,
RA   Huang H., Tang Z., Zhao Y., Roeder R.G., Shi X., Allis C.D., Li H.;
RT   "Molecular coupling of histone crotonylation and active transcription by
RT   AF9 YEATS domain.";
RL   Mol. Cell 62:181-193(2016).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-36; THR-161; VAL-172; GLN-435; HIS-441
RP   AND PRO-447.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Chromatin reader that recognizes and binds hyperacetylated
CC       chromatin and plays a role in the regulation of transcription, probably
CC       by chromatin remodeling and interaction with transcription factors
CC       (PubMed:18406326, PubMed:27105114). Regulates transcription by
CC       promoting the binding of the transcription factor GATA1 to its targets
CC       (By similarity). {ECO:0000250|UniProtKB:Q8K2F0,
CC       ECO:0000269|PubMed:18406326, ECO:0000269|PubMed:27105114}.
CC   -!- SUBUNIT: Interacts (via bromo domain 1) with GATA1 acetylated at 'Lys-
CC       312' and 'Lys-315'. Interacts (via bromo domain 1) with GATA2
CC       acetylated on lysine residues (By similarity). Interacts (via bromo
CC       domains) with acetylated lysine residues on the N-terminus of histone
CC       H2A, H2B, H3 and H4 (in vitro). {ECO:0000250|UniProtKB:Q8K2F0,
CC       ECO:0000269|PubMed:18406326, ECO:0000269|PubMed:22464331}.
CC   -!- INTERACTION:
CC       Q15059; P01106: MYC; NbExp=3; IntAct=EBI-1383460, EBI-447544;
CC       Q15059-2; O00505: KPNA3; NbExp=3; IntAct=EBI-13468085, EBI-358297;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q8K2F0}.
CC       Note=Detected on chromatin. {ECO:0000250|UniProtKB:Q8K2F0}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15059-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15059-2; Sequence=VSP_010247, VSP_010248;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The Bromo domains specifically recognize and bind acetylated
CC       histones. {ECO:0000269|PubMed:27105114}.
CC   -!- DISEASE: Note=A chromosomal aberration involving BRD3 is found in a
CC       rare, aggressive, and lethal carcinoma arising in midline organs of
CC       young people. Translocation t(15;9)(q14;q34) with NUTM1 which produces
CC       a BRD3-NUTM1 fusion protein. {ECO:0000269|PubMed:17934517}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA05393.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D26362; BAA05393.2; ALT_INIT; mRNA.
DR   EMBL; AY513270; AAS82952.1; -; mRNA.
DR   EMBL; AL445931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471090; EAW88113.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW88114.1; -; Genomic_DNA.
DR   EMBL; BC032124; AAH32124.1; -; mRNA.
DR   EMBL; Z81330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS6980.1; -. [Q15059-1]
DR   RefSeq; NP_031397.1; NM_007371.3. [Q15059-1]
DR   RefSeq; XP_006717354.1; XM_006717291.2. [Q15059-1]
DR   RefSeq; XP_011517354.1; XM_011519052.2. [Q15059-1]
DR   PDB; 2E7N; NMR; -; A=306-415.
DR   PDB; 2NXB; X-ray; 1.40 A; A/B=24-144.
DR   PDB; 2OO1; X-ray; 1.70 A; A/B/C/D=307-416.
DR   PDB; 2YW5; NMR; -; A=25-155.
DR   PDB; 3S91; X-ray; 2.06 A; A=24-144.
DR   PDB; 3S92; X-ray; 1.36 A; A=306-416.
DR   PDB; 5A7C; X-ray; 1.90 A; A/B/C/D=306-416.
DR   PDB; 5HFR; X-ray; 1.70 A; A/B/C/D=306-416.
DR   PDB; 5HJC; X-ray; 2.60 A; A=307-416.
DR   PDB; 6BGG; NMR; -; B=557-644.
DR   PDB; 6BGH; NMR; -; A=557-643.
DR   PDB; 6I41; X-ray; 1.90 A; B=245-253.
DR   PDB; 6I5P; X-ray; 1.81 A; B/D/F/H=245-253.
DR   PDB; 6I68; X-ray; 1.85 A; B/D/F/H=245-253.
DR   PDB; 6I7A; X-ray; 2.20 A; B/D/F/H=245-253.
DR   PDB; 6QJU; X-ray; 1.20 A; A/B=24-144.
DR   PDB; 6U4A; X-ray; 1.88 A; A/B=25-147.
DR   PDB; 6ULP; X-ray; 2.80 A; A/B=307-419.
DR   PDB; 7JMY; NMR; -; A=554-640.
DR   PDB; 7JQ8; NMR; -; A=554-640.
DR   PDB; 7JYN; NMR; -; A=554-640.
DR   PDB; 7JYZ; NMR; -; B=554-640.
DR   PDB; 7L72; X-ray; 1.50 A; A=306-416.
DR   PDB; 7L9L; X-ray; 1.55 A; A=306-416.
DR   PDB; 7LAY; X-ray; 1.45 A; A/B=24-144.
DR   PDB; 7LAZ; X-ray; 2.30 A; A/B=24-144.
DR   PDB; 7LB4; X-ray; 2.00 A; A/B=306-416.
DR   PDB; 7LBT; X-ray; 2.70 A; A/B/C/D=306-416.
DR   PDBsum; 2E7N; -.
DR   PDBsum; 2NXB; -.
DR   PDBsum; 2OO1; -.
DR   PDBsum; 2YW5; -.
DR   PDBsum; 3S91; -.
DR   PDBsum; 3S92; -.
DR   PDBsum; 5A7C; -.
DR   PDBsum; 5HFR; -.
DR   PDBsum; 5HJC; -.
DR   PDBsum; 6BGG; -.
DR   PDBsum; 6BGH; -.
DR   PDBsum; 6I41; -.
DR   PDBsum; 6I5P; -.
DR   PDBsum; 6I68; -.
DR   PDBsum; 6I7A; -.
DR   PDBsum; 6QJU; -.
DR   PDBsum; 6U4A; -.
DR   PDBsum; 6ULP; -.
DR   PDBsum; 7JMY; -.
DR   PDBsum; 7JQ8; -.
DR   PDBsum; 7JYN; -.
DR   PDBsum; 7JYZ; -.
DR   PDBsum; 7L72; -.
DR   PDBsum; 7L9L; -.
DR   PDBsum; 7LAY; -.
DR   PDBsum; 7LAZ; -.
DR   PDBsum; 7LB4; -.
DR   PDBsum; 7LBT; -.
DR   AlphaFoldDB; Q15059; -.
DR   SASBDB; Q15059; -.
DR   SMR; Q15059; -.
DR   BioGRID; 113715; 479.
DR   DIP; DIP-39755N; -.
DR   IntAct; Q15059; 25.
DR   MINT; Q15059; -.
DR   STRING; 9606.ENSP00000305918; -.
DR   BindingDB; Q15059; -.
DR   ChEMBL; CHEMBL1795186; -.
DR   GuidetoPHARMACOLOGY; 2725; -.
DR   GlyGen; Q15059; 5 sites, 1 O-linked glycan (5 sites).
DR   iPTMnet; Q15059; -.
DR   PhosphoSitePlus; Q15059; -.
DR   BioMuta; BRD3; -.
DR   DMDM; 12643726; -.
DR   EPD; Q15059; -.
DR   jPOST; Q15059; -.
DR   MassIVE; Q15059; -.
DR   MaxQB; Q15059; -.
DR   PaxDb; Q15059; -.
DR   PeptideAtlas; Q15059; -.
DR   PRIDE; Q15059; -.
DR   ProteomicsDB; 60414; -. [Q15059-1]
DR   ProteomicsDB; 60415; -. [Q15059-2]
DR   ABCD; Q15059; 1 sequenced antibody.
DR   Antibodypedia; 31966; 404 antibodies from 33 providers.
DR   DNASU; 8019; -.
DR   Ensembl; ENST00000303407.12; ENSP00000305918.6; ENSG00000169925.17. [Q15059-1]
DR   Ensembl; ENST00000371834.6; ENSP00000360900.2; ENSG00000169925.17. [Q15059-2]
DR   GeneID; 8019; -.
DR   KEGG; hsa:8019; -.
DR   MANE-Select; ENST00000303407.12; ENSP00000305918.6; NM_007371.4; NP_031397.1.
DR   UCSC; uc004cew.4; human. [Q15059-1]
DR   CTD; 8019; -.
DR   DisGeNET; 8019; -.
DR   GeneCards; BRD3; -.
DR   HGNC; HGNC:1104; BRD3.
DR   HPA; ENSG00000169925; Low tissue specificity.
DR   MIM; 601541; gene.
DR   neXtProt; NX_Q15059; -.
DR   OpenTargets; ENSG00000169925; -.
DR   PharmGKB; PA25415; -.
DR   VEuPathDB; HostDB:ENSG00000169925; -.
DR   eggNOG; KOG1474; Eukaryota.
DR   GeneTree; ENSGT00940000153385; -.
DR   HOGENOM; CLU_001499_0_4_1; -.
DR   InParanoid; Q15059; -.
DR   OMA; CYAFNPD; -.
DR   PhylomeDB; Q15059; -.
DR   TreeFam; TF317345; -.
DR   PathwayCommons; Q15059; -.
DR   SignaLink; Q15059; -.
DR   SIGNOR; Q15059; -.
DR   BioGRID-ORCS; 8019; 17 hits in 1097 CRISPR screens.
DR   ChiTaRS; BRD3; human.
DR   EvolutionaryTrace; Q15059; -.
DR   GeneWiki; BRD3; -.
DR   GenomeRNAi; 8019; -.
DR   Pharos; Q15059; Tchem.
DR   PRO; PR:Q15059; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q15059; protein.
DR   Bgee; ENSG00000169925; Expressed in nipple and 218 other tissues.
DR   ExpressionAtlas; Q15059; baseline and differential.
DR   Genevisible; Q15059; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   CDD; cd05497; Bromo_Brdt_I_like; 1.
DR   CDD; cd05498; Bromo_Brdt_II_like; 1.
DR   DisProt; DP03059; -.
DR   Gene3D; 1.20.1270.220; -; 1.
DR   Gene3D; 1.20.920.10; -; 2.
DR   InterPro; IPR043508; Bromo_Brdt_I.
DR   InterPro; IPR043509; Bromo_Brdt_II.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR027353; NET_dom.
DR   InterPro; IPR038336; NET_sf.
DR   Pfam; PF17035; BET; 1.
DR   Pfam; PF00439; Bromodomain; 2.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 2.
DR   SUPFAM; SSF47370; SSF47370; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 2.
DR   PROSITE; PS50014; BROMODOMAIN_2; 2.
DR   PROSITE; PS51525; NET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Bromodomain;
KW   Chromatin regulator; Chromosomal rearrangement; Coiled coil;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..726
FT                   /note="Bromodomain-containing protein 3"
FT                   /id="PRO_0000211181"
FT   DOMAIN          51..123
FT                   /note="Bromo 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          326..398
FT                   /note="Bromo 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          562..644
FT                   /note="NET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00857"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          78..80
FT                   /note="Acetylated histone H3 binding"
FT                   /evidence="ECO:0000269|PubMed:27105114"
FT   REGION          149..169
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          237..305
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          421..462
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          477..575
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          637..726
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          453..524
FT                   /evidence="ECO:0000255"
FT   COILED          645..684
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        14..29
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        247..266
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        273..305
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        498..524
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        535..551
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        652..673
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        697..726
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            647..648
FT                   /note="Breakpoint for translocation to form BDR3-NUTM1
FT                   fusion protein"
FT                   /evidence="ECO:0000269|PubMed:17934517"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         563
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   CROSSLNK        414
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         549..556
FT                   /note="QLKKGGKQ -> DHFLTCGV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010247"
FT   VAR_SEQ         557..726
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010248"
FT   VARIANT         36
FT                   /note="T -> N (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041913"
FT   VARIANT         161
FT                   /note="A -> T (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041914"
FT   VARIANT         172
FT                   /note="A -> V (in dbSNP:rs34609592)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041915"
FT   VARIANT         435
FT                   /note="K -> Q (in dbSNP:rs36093130)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041916"
FT   VARIANT         441
FT                   /note="R -> H (in dbSNP:rs56017928)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041917"
FT   VARIANT         447
FT                   /note="S -> P (in dbSNP:rs55754444)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041918"
FT   STRAND          29..31
FT                   /evidence="ECO:0007829|PDB:2YW5"
FT   HELIX           37..44
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           46..52
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   TURN            65..69
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           73..76
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           83..91
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           98..115
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           121..137
FT                   /evidence="ECO:0007829|PDB:6QJU"
FT   HELIX           310..323
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           328..331
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           332..334
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   TURN            340..344
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           348..351
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           358..366
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           373..390
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           396..413
FT                   /evidence="ECO:0007829|PDB:3S92"
FT   HELIX           558..561
FT                   /evidence="ECO:0007829|PDB:6BGH"
FT   HELIX           567..569
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   HELIX           574..585
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   HELIX           589..602
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   HELIX           604..608
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   STRAND          611..613
FT                   /evidence="ECO:0007829|PDB:6BGH"
FT   STRAND          615..617
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   TURN            618..620
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   HELIX           623..636
FT                   /evidence="ECO:0007829|PDB:6BGG"
FT   TURN            640..642
FT                   /evidence="ECO:0007829|PDB:6BGG"
SQ   SEQUENCE   726 AA;  79542 MW;  64F526FC3C1033AA CRC64;
     MSTATTVAPA GIPATPGPVN PPPPEVSNPS KPGRKTNQLQ YMQNVVVKTL WKHQFAWPFY
     QPVDAIKLNL PDYHKIIKNP MDMGTIKKRL ENNYYWSASE CMQDFNTMFT NCYIYNKPTD
     DIVLMAQALE KIFLQKVAQM PQEEVELLPP APKGKGRKPA AGAQSAGTQQ VAAVSSVSPA
     TPFQSVPPTV SQTPVIAATP VPTITANVTS VPVPPAAAPP PPATPIVPVV PPTPPVVKKK
     GVKRKADTTT PTTSAITASR SESPPPLSDP KQAKVVARRE SGGRPIKPPK KDLEDGEVPQ
     HAGKKGKLSE HLRYCDSILR EMLSKKHAAY AWPFYKPVDA EALELHDYHD IIKHPMDLST
     VKRKMDGREY PDAQGFAADV RLMFSNCYKY NPPDHEVVAM ARKLQDVFEM RFAKMPDEPV
     EAPALPAPAA PMVSKGAESS RSSEESSSDS GSSDSEEERA TRLAELQEQL KAVHEQLAAL
     SQAPVNKPKK KKEKKEKEKK KKDKEKEKEK HKVKAEEEKK AKVAPPAKQA QQKKAPAKKA
     NSTTTAGRQL KKGGKQASAS YDSEEEEEGL PMSYDEKRQL SLDINRLPGE KLGRVVHIIQ
     SREPSLRDSN PDEIEIDFET LKPTTLRELE RYVKSCLQKK QRKPFSASGK KQAAKSKEEL
     AQEKKKELEK RLQDVSGQLS SSKKPARKEK PGSAPSGGPS RLSSSSSSES GSSSSSGSSS
     DSSDSE
//
